Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury
Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury
Not yet recruiting · NCT07518303 · Registry updated 2026-06-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Infections, Inflammation, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Sepsis, Systemic Inflammatory Response Syndrome, Urogenital Diseases, acute kidney injury, kidney disorder, kidney failure, urinary system disorder | Not yet recruiting | Phase 4 | 2026-06-03 | NCT07518303 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Jianfeng Xie | 2 |
| Southeast University, China | 36 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||